A theme in which tighter regenerative medicine systems and regulations in China reduce orders for related materials such as culture media and bags for the Chinese market, affecting revenue and profit in the Life Sciences business. It concerns the impact of changes in China’s regulatory framework on customer demand and orders, rather than delays in obtaining approval for the company’s own products.